Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.
Kura Oncology, Inc. reports news on its precision oncology business, including commercialization of KOMZIFTI™ (ziftomenib), an FDA-approved once-daily oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia. Company updates also cover small-molecule drug candidates designed to target cancer signaling pathways across hematologic malignancies and solid tumors.
Recurring KURA developments include financial results, corporate updates, clinical data presentations, collaboration-related milestones, healthcare conference participation and Nasdaq inducement grants. News on darlifarnib (KO-2806) follows the company’s farnesyl transferase inhibitor program, including studies in combination with cabozantinib for clear cell renal cell carcinoma.
Kura Oncology, Inc. (Nasdaq: KURA) announced participation in three upcoming virtual investor conferences. CEO Troy Wilson will present at the Credit Suisse 29th Annual Healthcare Conference on November 11, 2020, at 10:15 a.m. ET. CFO Marc Grasso will speak at the Stifel Virtual Healthcare Conference on November 16, 2020, at 1:20 p.m. ET. Additionally, a pre-recorded fireside chat with Dr. Wilson will be available on Kura's website during the Piper Sandler 32nd Annual Healthcare Conference from December 1-3, 2020. Live audio webcasts will also be accessible on Kura's IR website.
Kura Oncology (KURA) will release its third quarter 2020 financial results on November 5, 2020, before U.S. markets open. A conference call and webcast will follow at 8 a.m. ET to discuss the results and provide a corporate update. The company focuses on developing precision cancer treatments, with its lead candidate, tipifarnib, in a registration-directed trial for HRAS mutant head and neck cancer. Kura also has KO-539, a menin inhibitor in Phase 1/2A trials for acute myeloid leukemia.
Kura Oncology has unveiled new preclinical data supporting the use of tipifarnib in treating HRAS/PI3K-dependent tumors, which account for up to 50% of head and neck squamous cell carcinoma (HNSCC) cases. The company plans to initiate a Phase 1/2 proof-of-concept study combining tipifarnib with a PI3Kα inhibitor in relapsed/refractory HNSCC. Current estimates suggest that 20% of HNSCC patients overexpress HRAS while 35% have PIK3CA mutations. Kura's ongoing AIM-HN trial focuses on HRAS mutant HNSCC, which affects 4-8% of patients.
Kura Oncology, a clinical-stage biopharmaceutical company, announced that preliminary data from its KOMET-001 study will be presented at the 62nd ASH Annual Meeting on December 5, 2020. This ongoing trial evaluates the safety and efficacy of KO-539, an oral menin inhibitor for patients with relapsed/refractory acute myeloid leukemia (AML). Data will be available on the ASH website on November 5, 2020. The presentation aims to assess anti-leukemic activity in specific genetic subgroups, highlighting the potential of KO-539 in addressing high unmet medical needs.
Kura Oncology (Nasdaq: KURA) announced that CEO Troy Wilson will participate in two virtual investor conferences. The events include a fireside chat at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 11:30 a.m. ET, and another at the 2020 Cantor Virtual Global Healthcare Conference on September 16, 2020, at 4:00 p.m. ET. Live webcasts will be accessible on Kura’s website, with archived replays available for 30 days. Kura is focused on precision medicines for cancer, with drug candidates targeting critical pathways in cancer treatment.
Kura Oncology announced the appointment of Stephen Dale, M.D., as the new Chief Medical Officer. Dr. Dale brings extensive experience from his previous role at Kyowa Kirin, focusing on oncology. His leadership is expected to enhance Kura's clinical development efforts, particularly for tipifarnib in HRAS-dependent head and neck cancers and KO-539 in acute myeloid leukemia.
Former acting CMO Bridget Martell will transition to Senior Scientific Advisor, continuing her contributions to Kura's strategic initiatives.
Kura Oncology, a clinical-stage biopharmaceutical company, will participate in the 2020 Wedbush PacGrow Healthcare Virtual Conference. CEO Troy Wilson is set to present on August 11, 2020, at 2:20 p.m. ET. The conference runs from August 11-12, 2020, and a live audio webcast will be available on the company’s website. Kura’s pipeline includes two drug candidates targeting cancer pathways, with tipifarnib in a pivotal trial for HRAS mutant head and neck cancer and KO-539 in Phase 1/2A trials for acute myeloid leukemia.
Kura Oncology, Inc. (Nasdaq: KURA) is set to release its second quarter 2020 financial results on August 6, 2020, after U.S. markets close. Management will hold a webcast and conference call at 4:30 p.m. ET to discuss these results and provide a corporate update. Kura focuses on developing precision medicines for cancer with two promising drug candidates: tipifarnib, which targets HRAS mutant head and neck squamous cell carcinoma, and KO-539, aimed at treating acute myeloid leukemia.
Kura Oncology, a clinical-stage biopharmaceutical company, announced its participation in the JMP Securities Hematology & Oncology Forum on June 18, 2020. CEO Troy Wilson will engage in a fireside chat at 10:40 a.m. ET. The virtual event runs from June 18-19, and interested parties can access a live audio webcast via Kura's website, with an archived replay available for 30 days after the event.
Kura's pipeline includes drug candidates targeting cancer pathways, with its lead candidate being tipifarnib for HRAS mutant head and neck squamous cell carcinoma.
Kura Oncology, Inc. (Nasdaq: KURA) announced acceptance of three abstracts for tipifarnib presentation at the ASCO Virtual Scientific Program scheduled for May 29-31, 2020. Highlights include an oral presentation on the drug's single-agent activity in solid tumors with HRAS mutations, featuring data from the RUN-HN Phase 2 trial on HNSCC patients. Tipifarnib, a farnesyltransferase inhibitor, has Fast Track designation for treating HRAS mutant HNSCC, with prior studies indicating durable anti-cancer activity. The abstracts are accessible on ASCO's website.